Stifel Nicolaus initiated its coverage on ImunoGen IMGN with a Hold rating.
Stifel Nicolaus said, "Given the relatively short lifespan of the T-DM1 royalty stream (compared to the branded life span of most biologic therapies, such as Epogen, Rituxan, and Herceptin itself, which can run 15-20 years), we expect ImmunoGen to re-invest the royalties as opposed to driving EPS growth. As a result, we believe there is little upside potential for the shares from current levels, even if T-DM1 sales exceed expectations."
ImmunoGen closed at $13.92 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in